INTRODUCTION {#sec1-ZoolRes-40-3-205}
============

Protease inhibitors occur naturally in living organisms, including animals ([@B26-ZoolRes-40-3-205];[@B31-ZoolRes-40-3-205]; [@B32-ZoolRes-40-3-205]; [@B12-ZoolRes-40-3-205]), plants ([@B11-ZoolRes-40-3-205]; [@B22-ZoolRes-40-3-205]), fungi ([@B23-ZoolRes-40-3-205]), and bacteria ([@B28-ZoolRes-40-3-205]). They have multifunctional roles in many physiological processes and play an important role in biological functions of venomous animals, such as in predation ([@B2-ZoolRes-40-3-205]) and defense ([@B1-ZoolRes-40-3-205]). To prevent clotting during blood feeding from a host, hematophagous animals have developed various mechanisms to interfere with blood coagulation ([@B16-ZoolRes-40-3-205]). Among the inhibitors involved in coagulation, protease inhibitors are the most prominent anticoagulants currently described and characterized from leeches ([@B5-ZoolRes-40-3-205]) and insects ([@B4-ZoolRes-40-3-205]; [@B18-ZoolRes-40-3-205]).

There are at least four types of protease inhibitors, including serine, cysteine, aspartic, and metalloprotease inhibitors ([@B14-ZoolRes-40-3-205]). The Kazal family is one of the best-known groups of serine protease inhibitors ([@B21-ZoolRes-40-3-205]). Kazal-type inhibitory can be sorted into classical and non-classical Kazal domains. The classical Kazal domain has two residues between cys4 and cys5, whereas the non-classical Kazal inhibitor has a spacer region between cys4 and cys5, ranging from three to seven residues ([@B19-ZoolRes-40-3-205]). There are highly homologous three-dimensional structures in the Kazal-type serine proteinase inhibitors regardless of length of amino acid sequences between the cysteines and amino acid sequence variation ([@B6-ZoolRes-40-3-205]). The P1 residue, located in the second amino acid downstream of the second conserved cysteine residue, is inserted into the S1 specificity pocket of the protease in a substrate-like way ([@B3-ZoolRes-40-3-205]; [@B13-ZoolRes-40-3-205]).

Several Kazal-type serine protease inhibitors have been characterized from leeches. A few "non-classical" Kazal inhibitors have been reported from different leeches, including bdellin-B-3 ([@B7-ZoolRes-40-3-205]), bdellin-KL ([@B10-ZoolRes-40-3-205]), and bdellin-HM ([@B12-ZoolRes-40-3-205]). In this study, bdellin-HM-2 was purified and characterized from the leech *H. manillensis*. To the best of our knowledge, bdellin-HM-2 is the first Kazal-type serine protease inhibitor displaying anticoagulant properties identified from *H. manillensis*.

MATERIALS AND METHODS {#sec2-ZoolRes-40-3-205}
=====================

Collection of crude extracts {#sec2dot1-ZoolRes-40-3-205}
----------------------------

The *H. manillensis* leeches were purchased from Jinbian aquafarm, Qinzhou City, Guangxi Province in China. The leeches were still alive when transported to the laboratory. We prepared the crude extracts from the leech heads as described previously ([@B12-ZoolRes-40-3-205]). In short, leech heads were separated from the bodies, washed in 0.9% saline, quickly frozen, and then ground in liquid nitrogen.

Purification of bdellin-HM-2 {#sec2dot2-ZoolRes-40-3-205}
----------------------------

Purification of bdellin-HM2 followed similar methods described in our previous published article ([@B12-ZoolRes-40-3-205]). Briefly, crude extracts were dissolved in 50 mmol/L Tris-HCl buffer (pH 8.9) and subsequently separated by a DEAE Sephadex A-50 column (5 cm diameter, 60 cm length, GE, USA). Elution was performed at a flow rate of 15 mL/h at 4 °C and 3.0 mL fractions were collected in separate tubes. The absorbance of the fractions was monitored at both 215 and 280 nm. Fractions that could prolong the activated partial thromboplastin time (aPTT) were pooled and lyophilized prior to further purification. The powder from the previous step was dissolved and loaded for reverse-phase high-performance liquid chromatography (RP-HPLC) on a C~18~ column (Waters, Milford, MA, USA, 5 μm particle size, 250 mm×4.6 mm). Elution was carried out with a linear gradient of 10%--60% solution B (99.9% acetonitrile, 0.1% TFA) for 60 min at a flow rate of 1 mL/min. The eluted fraction that prolonged aPTT was collected.

Mass spectrometric analysis and peptide sequencing {#sec2dot3-ZoolRes-40-3-205}
--------------------------------------------------

The molecular weight of the collected fraction was analyzed by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS, Autoflex speed TOF/TOF, Bruker Daltonik GmbH, Bruker Corporation, Germany) using positive ion and linear mode, with specific operating parameters including a 20 kV ion acceleration voltage, 50-time accumulation for single scanning, and 0.1% accuracy of mass determinations. The partial peptide sequence of the N-terminal was determined by automatic Edman degradation on a pulsed liquid-phase sequencer (PPSQ-31A, Shimadzu Corporation, Japan).

RNA extraction and cDNA library construction {#sec2dot4-ZoolRes-40-3-205}
--------------------------------------------

Total RNA from the head of *H. manillensis* was extracted using Trizol reagent (Life Technologies, Carlsbad, CA, USA) according to the manufacturer's instructions and was dissolved in RNase-Free water. A SMART™ PCR cDNA construction kit (Clontech, Palo Alto, CA, USA) was used for synthesizing cDNA, as described previously ([@B12-ZoolRes-40-3-205]).

Screening of cDNA encoding bdellin-HM-2 {#sec2dot5-ZoolRes-40-3-205}
---------------------------------------

To screen the cDNA encoding the precursor of bdellin-HM-2, synthesized cDNA was used as the template for PCR, following previously described methods ([@B12-ZoolRes-40-3-205]). Briefly, two pairs of oligonucleotide primers ([Table 1](#ZoolRes-40-3-205-t001){ref-type="table"}) were used in PCR reactions, where primers 1 and 3 were designed according to the partial N-terminal sequence of bdellin-HM-2 and primers 2 and 4 were from the SMART™ PCR cDNA construction kit. The PCR conditions were as described previously ([@B12-ZoolRes-40-3-205]).

###### Primers used for cDNA cloning of bdellin-HM-2

  Primer   Sequence (5\'--3\')
  -------- -------------------------
  1        AACAGGTTTGCGGAAGT
  2        AAGCAGTGGTATCAACGCAGAGT
  3        AATTCCAGGGTACAGACG
  4        ATTCTAGAGGCCGAGGCGGCCGA

Primers 1 and 2 for signal peptide cloning; primers 3 and 4 for mature peptide cloning.

Effects of bdellin-HM-2 on blood coagulation {#sec2dot6-ZoolRes-40-3-205}
--------------------------------------------

For aPTT assay, the aPTT reagent (50 μL, F008-1, Nanjing Jiancheng Bioengineering Institute, China) was incubated with 50 μL of plasma and different concentrations of bdellin-HM-2 (0.7 and 1.4 μmol/L). After 3-min incubation, CaCl~2~ (50 μL, 25 mmol/L) preheated at 37 °C for 5 min was added, and the clotting curve was monitored at 650 nm using an enzyme-labeled instrument (Epoch BioTek, USA) for 2 min. To test the prothrombin time (PT), plasma (50 μL) was incubated with different concentrations of bdellin-HM-2 (0.7 and 1.4 μmol/L) for 3 min at 37 °C, after which the PT reagent (100 μL, F007, Nanjing Jiancheng Bioengineering Institute, China) preheated at 37 °C for 15 min was added and the clotting curve was monitored at 650 nm using the enzyme-labeled instrument for 30 s.

Effects of bdellin-HM-2 on proteases {#sec2dot7-ZoolRes-40-3-205}
------------------------------------

Effects of bdellin-HM-2 on proteases, including trypsin, elastase, chymotrypsin, kallikrein, factor XIIa (FXIIa), factor XIa (FXIa), factor Xa (FXa), thrombin, and plasmin were tested using the corresponding chromogenic substrates. The testing enzyme was incubated with different concentrations (0, 0.7, 1.4, 2.8, and 5.6 μmol/L) of bdellin-HM-2 in 60 μL of 50 mmol/L Tris buffer (pH 7.4) for 5 min, with a certain concentration of chromogenic substrate then added. Absorbance at 405 nm was monitored immediately and the kinetic curve was recorded using the enzyme-labeled instrument for 30 min. Bovine pancreas trypsin, elastase, chymotrypsin, and plasmin were all obtained from Sigma (USA) and the enzyme concentrations used were 800, 400, 400, and 20 nmol/L, respectively. The corresponding chromogenic substrates (Sigma, USA) were Gly-Arg-*p*-nitroanilide dihydrochloride for trypsin, *N*-methoxysuccinyl-Ala-Ala-Pro-Val-*p*-nitroanilide for elastase, *N*-succinyl-Gly-Gly-Phe-*p*-nitroanilide for chymotrypsin, and Gly-Arg-*p*-nitroanilide dihydrochloride for plasmin. The concentration of all substrates in the reactions was 0.2 mmol/L. The concentrations used for kallikrein, FXIa, and FXa (Enzyme Research Laboratory, USA) were 400, 400, and 20 nmol/L, respectively, and the corresponding chromogenic substrates were *H-D*-Pro-Phe-Arg-*p*NA·2HCl (Hyphen Biomed, France), *H-D*-Pro-Phe-Arg-*p*NA·2HCl (Hyphen Biomed, France), and CH~3~OCO-*D*-CHA-Gly-Arg-*p*NA-AcOH (Sigma, USA), respectively. The concentration of all three substrates in the reaction was 0.2 mmol/L. Human thrombin (Sigma, USA, 10 nmol/L) and FXIIa (Enzyme Research Laboratories, USA, 10 nmol/L) were reacted with 0.2 mmol/L chromogenic substrate of *H-D*-Phe-Pip-Arg-*p*Na·2HCl (Hyphen Biomed, France) and *H-D*-Pro-Phe-Arg-*p*NA·2HCl (Hyphen Biomed, France), respectively.

RESULTS {#sec3-ZoolRes-40-3-205}
=======

Purification of bdellin-HM-2 {#sec3dot1-ZoolRes-40-3-205}
----------------------------

The crude extracts from *H. manillensis* were resolved into several fractions by DEAE Sephadex A-50 column. The fraction that prolonged the aPTT was indicated by a bar ([Figure 1](#ZoolRes-40-3-205-f001){ref-type="fig"}A). We then obtained the purified peptide exerting an aPTT inhibitory effect, named bdellin-HM-2 (indicated by an arrow in [Figure 1](#ZoolRes-40-3-205-f001){ref-type="fig"}B), using a C~18~ RP-HPLC column. MALDI-TOF-MS showed that bdellin-HM-2 had a molecular weight (MW) of 14141.5 ([Figure 1](#ZoolRes-40-3-205-f001){ref-type="fig"}C).

![Purification of bdellin-HM-2 from *H. manillensis*](ZoolRes-40-3-205-g001){#ZoolRes-40-3-205-f001}

Primary structure of bdellin-HM-2 {#sec3dot2-ZoolRes-40-3-205}
---------------------------------

Based on automatic Edman degradation, the partial N-terminal sequence of bdellin-HM-2 was determined to be ETECVCTLELKQVCGS. According to the N-terminal sequence, degenerate primers were designed ([Table 1](#ZoolRes-40-3-205-t001){ref-type="table"}) to clone the cDNA encoding the precursor of bdellin-HM-2 from the cDNA library. A 399 bp cDNA encoding the precursor of bdellin-HM-2 was obtained. The cDNA had an open reading frame (ORF) of 396 nucleotides coding a pro-protein of 132 amino acids, including a signal peptide of 18 residues (indicated by box) and mature bdellin-HM-2 of 114 residues ([Figure 2](#ZoolRes-40-3-205-f002){ref-type="fig"}A). The theoretical MW of mature bdellin-HM-2 was 13144.78, which was not consistent with the observed mass by mass spectrometry analysis ([Figure 1](#ZoolRes-40-3-205-f001){ref-type="fig"}C). This inconsistency may be due to post-translational modification of the protein. Sequence alignment showed similarity to bdellin-KL ([@B10-ZoolRes-40-3-205]), bdellin-B-3 ([@B7-ZoolRes-40-3-205]), and bdellin-HM ([@B12-ZoolRes-40-3-205]), which are "non-classical" Kazal serine protease inhibitors ([Figure 2](#ZoolRes-40-3-205-f002){ref-type="fig"}B). Multiple sequence alignment showed that the six cysteine residues and threonine-tyrosine residues were highly conserved among different species ([Figure 2](#ZoolRes-40-3-205-f002){ref-type="fig"}C). There were multiple HHXDD and HXDD motifs at the C-terminus of bdellin-HM-2.

![cDNA sequence encoding bdellin-HM-2 precursor and sequence alignment with other protease inhibitors](ZoolRes-40-3-205-g002){#ZoolRes-40-3-205-f002}

Anticoagulant activity of bdellin-HM-2 {#sec3dot3-ZoolRes-40-3-205}
--------------------------------------

Under the assay conditions, bdellin-HM-2 exerted anticoagulatory activity by inhibiting aPTT ([Figure 3](#ZoolRes-40-3-205-f003){ref-type="fig"}A), whereas no inhibitory activity was observed on PT ([Figure 3](#ZoolRes-40-3-205-f003){ref-type="fig"}B). Compared with the control with an aPTT of \~60 s, the aPTT was prolonged to \~100 s after 0.7 and 1.4 μmol/L bdellin-HM-2 treatment, suggesting that bdellin-HM-2 acts on the intrinsic pathway. Bdellin-HM-2 had no effect on trypsin, elastase, chymotrypsin, kallikrein, FXIIa, FXIa, FXa, thrombin, or plasmin ([Figure 3](#ZoolRes-40-3-205-f003){ref-type="fig"}C). All enzyme activity test results were plotted ([Figure 4](#ZoolRes-40-3-205-f004){ref-type="fig"}).

![Effects of bdellin-HM-2 on aPTT](ZoolRes-40-3-205-g003){#ZoolRes-40-3-205-f003}

![Bdellin-HM-2 had no effect on proteases](ZoolRes-40-3-205-g004){#ZoolRes-40-3-205-f004}

DISCUSSION {#sec4-ZoolRes-40-3-205}
==========

Several protease inhibitors exerting anticoagulant effects have been found from leeches ([@B9-ZoolRes-40-3-205]; [@B17-ZoolRes-40-3-205]; [@B25-ZoolRes-40-3-205]; [@B24-ZoolRes-40-3-205]; [@B27-ZoolRes-40-3-205]; [@B29-ZoolRes-40-3-205]). In this report, a novel protease inhibitor (bdellin-HM-2) with anticoagulant effects was purified and further characterized from *H. manillensis* for the first time. The cDNA encoding bdellin-HM-2 precursor was cloned from the cDNA library, and the mature bdellin-HM-2 consisted of 114 amino acid residues. MALDI-TOF-MS showed that the MW of bdellin-HM-2 was 14141.5, compared to the theoretical molecular weight of 13144.78, a difference of 996.72, which is not consistent with the theoretical value. Research shows glycosylation influences the function of protein, governs physiology, and contributes to disease ([@B20-ZoolRes-40-3-205]). We speculated that bdellin-HM-2 was O-glycosylated at Thr-20, Thr-25, Ser-34, Thr-38, and Thr-46. ([@B8-ZoolRes-40-3-205]), although further research on these O-glycosylation sites should be performed in the future.

Kazal-type inhibitors with one or more Kazal domains are characterized by multiple HHXDD and HXDD motifs in their amino acid sequences ([@B13-ZoolRes-40-3-205]) and by their highly homologous three-dimensional structures ([@B30-ZoolRes-40-3-205]). Each Kazal domain usually contains six conserved cysteine residues forming three intra-molecular disulfide bridges ([@B13-ZoolRes-40-3-205]; [@B15-ZoolRes-40-3-205]). P1 residue, which contributes to the inhibitory specificity, is located at the second position after the second cysteine residue of the Kazal domain ([@B3-ZoolRes-40-3-205]). Although bdellin-HM-2 showed high similarity to bdellin-HM and bdellin-KL by sequence analysis and belongs to the family of non-classical Kazal domains, enzyme activity tests showed that bdellin-HM-2 had no inhibitory effects on trypsin, elastase, chymotrypsin, kallikrein, FXIIa, FXIa, FXa, thrombin, or plasmin under the assay conditions. Sequence alignment showed that the P1 residue of bdellin-HM-2 was different from bdellin-HM, bdellin-KL, and bdellin-B-3. The difference in P1 residue was considered the cause of the enzyme activity test results.

Bdellin-HM-2 prolonged the aPTT, implying that bdellin-HM-2 functioned to help *H. manillensis* obtain a blood meal by inhibiting blood coagulation. Results showed that the activity was dose-independent. Further work to identify the target of bdellin-HM-2 in blood is necessary. Blood-sucking animals obtain a blood meal by overcoming the host's natural blood coagulation ([@B4-ZoolRes-40-3-205]; [@B5-ZoolRes-40-3-205]; [@B16-ZoolRes-40-3-205]; [@B18-ZoolRes-40-3-205]). The anticoagulant peptide obtained from *H. manillensis* not only facilitates our understanding of the mechanism of blood feeding for *H. manillensis*, but also provides a new candidate for the development of clinical anticoagulant drugs.

In conclusion, bdellin-HM-2 identified from *H. manillensis* prolonged the aPTT but exhibited no influence on PT and no inhibitory activity on trypsin, elastase, chymotrypsin, kallikrein, FXIIa, FXIa, FXa, thrombin, or plasmin under the assay conditions. Further research on O-glycosylation sites will be performed in the future. Bdellin-HM-2 is the first identified Kazal-type serine protease inhibitor from *H. manillensis* that shows a potent anticoagulant effect.
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